Skip to main content
SpringerLink
Log in

Follow up survey for implementation of fixed-dosing of monoclonal antibodies

  • Short Research Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Similar to the earlier anti-cancer therapies, monoclonal antibodies were introduced in bodysize-based schedules, despite the fact that body size only modestly effects the distribution, elimination and efficacy of monoclonal antibodies. Fixed-dosing of nivolumab and pembrolizumab has recently been approved by the European Medicines Agency. Objective To investigate the implementation of fixed-dosing of nivolumab, pembrolizumab and other monoclonal antibodies in the treatment of cancer. Method An online questionnaire was distributed among Dutch hospitals in January 2019. Results The majority of the hospitals (> 60%) responded, with a good representation of the characteristics of the hospitals in the Netherlands. Most hospitals which prescribe nivolumab and/or pembrolizumab have introduced fixed-dose-based schedules. However, the dosing of the other monoclonal antibodies was still based on body size. Conclusion Fixed-dosebased schedules of nivolumab and pembrolizumab have been rapidly implemented in most Dutch hospitals after approval of the European Medicines Agency. Despite emerging evidence which supports fixed-dose-based schedules for almost all the other monoclonal antibodies, its implementation stays behind. To increase the acceptance of fixed-dose-based schedules of monoclonal antibodies in the guidelines, additional studies may be needed, which focus on evaluating exposure, activity and cost effectiveness with the attempt to uncover the exact savings in costs for patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212–21.

    Article  CAS  Google Scholar 

  2. Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther. 2018;103(4):582–90.

    Article  CAS  Google Scholar 

  3. Mukherjee S, Ibrahimi S, Machiorlatti M, Roman D, Saleem R, Hassan A, et al. Personalized dosing versus fixed dosing of immune checkpoint inhibitors. Am J Ther. 2018;25(6):e767–8.

    Article  Google Scholar 

  4. OPDIVO Procedural steps taken and scientific information after the authorisation [Internet]. https://www.ema.europa.eu/en/documents/procedural-steps-after/opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 09 Sept 2019.

  5. Keytruda Procedural steps taken and scientific information after the authorisation [Internet]. https://www.ema.europa.eu/en/documents/procedural-steps-after/keytruda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 09 Sept 2019.

  6. Archief Rapportage Enquête Jaarcijfers Ziekenhuizen [Internet]. https://www.dhd.nl/producten-diensten/ejz/Paginas/Archief-rapportage-ejz.aspx. Accessed 09 Sept 2019.

  7. Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer BioMed Central. 2017;16(5):43.

    Article  Google Scholar 

  8. Bayle A, Besse B, Annereau M, Bonastre J. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? Eur J Cancer. 2019;113:28–31.

    Article  Google Scholar 

  9. Goldstein DA, Gordon N, Davidescu M, Leshno M, Steuer CE, Patel N, et al. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer. JNCI J Natl Cancer Inst. Oxford University Press. 2017;109(11).

  10. Tartarone A, Lerose R, Aieta M. Pros and cons of monoclonal antibodies fixed dosing administration in cancer patients. Biomed J Sci & Tech Res. 2018;4(2):3785–6.

    Google Scholar 

Download references

Acknowledgements

We would like to thank all Dutch pharmacies for their attribution to this study.

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, PO Box 90203, 1066 CX, Amsterdam, The Netherlands

    Kimberley M. Heinhuis

  2. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Jos H. Beijnen & Jeroen J. M. A. Hendrikx

  3. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

    Jos H. Beijnen

  4. Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Jeroen J. M. A. Hendrikx

Authors
  1. Kimberley M. Heinhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeroen J. M. A. Hendrikx
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberley M. Heinhuis.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heinhuis, K.M., Beijnen, J.H. & Hendrikx, J.J.M.A. Follow up survey for implementation of fixed-dosing of monoclonal antibodies. Int J Clin Pharm 42, 3–6 (2020). https://doi.org/10.1007/s11096-020-00971-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-00971-z

Keywords

Search

Navigation